Plain-English translation of NCT06762431 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination treatment for chronic lymphocytic leukemia (CLL) that hasn't responded to standard drugs. The treatment involves giving you specially engineered immune cells called CAR T cells along with , a medication that helps boost your immune system. Researchers want to see if this combination is safe and effective at fighting back against this type of blood cancer.
Many people with CLL stop responding to their usual medications, leaving them without good options. This trial is exploring whether combining engineered immune cells with this medication might help patients whose cancer has become resistant to standard treatments.
You likely qualify if…
You likely don't qualify if…
You would first continue taking your current medication for 3 months, then receive additional medications to prepare your body. Next, doctors would collect your own immune cells through a procedure, engineer them in the lab to recognize your cancer cells, and then give them back to you as an infusion. You would then take the medication by mouth for several days, and return for monitoring visits to check how well the treatment is working and watch for any side effects. Depending on your response, you may receive additional treatment over several months.
AI-generated summary from trial data · Aug 28, 2026 · Not medical advice
Belarus